Chemonaïveté in inoperable malignant bowel obstruction

Letter to the Editor


Chemonaïveté in inoperable malignant bowel obstruction


Saber Boutayeb, MD, Ibrahim El Ghissassi, MD, Hind Mrabti, Prof, Hassan Errihani, Prof


doi: https://doi.org/10.3747/co.24.3362

The Editor

Current Oncology

26 June 2016

We are writing concerning the article titled “Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer” recently published in your journal by Yang et al.1.

First, the study showed very interesting results. We know that malignant bowel obstruction occurs mostly in the terminal stages of gastric cancer, whereas fluoropyrimidines are usually given in first-line treatment2,3. In the Yang et al. study, patients were excluded if they had received chemotherapy or radiotherapy within the preceding 28 days; however, the authors did not specify whether the patients were chemonaïve. In our opinion, that information is very important to the interpretation of the results.

CONFLICT OF INTEREST DISCLOSURES

We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.

AUTHOR AFFILIATIONS

Department of Medical Oncology, National Institute of Oncology, University Mohammed V, Morocco.

REFERENCES

1. Yang S, Li S, Yu H, et al. Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer. Curr Oncol 2016;23:e248–52.
cross-ref  pubmed  pmc  

2. Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management and factors influencing spontaneous resolution. Cancer Manag Res 2012;4:159–69.
cross-ref  pmc  

3. Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver 2013;7:385–93.
cross-ref  pubmed  pmc  


Correspondence to: Saber Boutayeb, Institut National d’Oncologie, Avenue Allal Fassi, 10100, Quartier Irfane, Rabat, Maroc. E-mail: saber.boutayeb@um5s.net.ma

(Return to Top)



Current Oncology, VOLUME 24, NUMBER 1, February 2017








Copyright © 2017 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)